The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
USP18-Based Negative Feedback Control Is Induced by Type I and Type III Interferons and Specifically Inactivates Interferon α Response
Open accessAbstract
Type I interferons (IFN) are cytokines that are rapidly secreted upon microbial infections and regulate all aspects of the immune response. In humans 15 type I IFN subtypes exist, of which IFN α2 and IFN β are used in the clinic for treatment of different pathologies. IFN α2 and IFN β are non redundant in their expression and in their potency to exert specific bioactivities. The more recently identified type III IFNs (3 IFN λ or IL-28/IL-29) bind an unrelated cell-type restricted receptor. Downstream of these two receptor complexes is a shared Jak/Stat pathway. Several mechanisms that contribute to the shut down of the IFN-induced signaling have been described at the molecular level. In particular, it has long been known that type I IFN induces the establishment of a desensitized state. In this work we asked how the IFN-induced desensitization integrates into the network built by the multiple type I IFN subtypes and type III IFNs. We show that priming of cells with either type I IFN or type III IFN interferes with the cell's ability to further respond to all IFN α subtypes. Importantly, primed cells are differentially desensitized in that they retain sensitivity to IFN β. We show that USP18 is necessary and sufficient to induce differential desensitization, by impairing the formation of functional binding sites for IFN α2. Our data highlight a new type of differential between IFNs α and IFN β and underline a cross-talk between type I and type III IFN. This cross-talk could shed light on the reported genetic variation in the IFN λ loci, which has been associated with persistence of hepatitis C virus and patient's response to IFN α2 therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,514
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
Thomas, D. L., Thio, C. L., Martin, M. P., Qi, Y., Ge, D., O’hUigin, C., Kidd, J., Kidd, K., Khakoo, S. I., Alexander, G., et al. (2009) · Nature · doi:10.1038/nature08463 · Cited by 2,150
Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.449 · Cited by 2,141
IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex
Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F., Dickensheets, H., & Donnelly, R. P. (2003) · Nature Immunology · doi:10.1038/ni875 · Cited by 1,868
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Study, F. T. H. C., Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.447 · Cited by 1,826
Interferons at age 50: past, current and future impact on biomedicine
Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., & Stark, G. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2422 · Cited by 1,154
Sommereyns, C., Paul, S., Staeheli, P., & Michiels, T. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000017 · Cited by 772
Interferon signaling and treatment outcome in chronic hepatitis C
Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H. T., Christen, V., Terracciano, L., Filipowicz, W., & Heim, M. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707882105 · Cited by 642
Ank, N., West, H., Bartholdy, C., Eriksson, K., Thomsen, A. R., & Paludan, S. R. (2006) · Journal of Virology · doi:10.1128/jvi.80.9.4501-4509.2006 · Cited by 596
Marcello, T., Grakoui, A., Barba–Spaeth, G., Machlin, E. S., Kotenko, S. V., Macdonald, M. R., & Rice, C. M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.052 · Cited by 561
UBP43 (USP18) Specifically Removes ISG15 from Conjugated Proteins
Malakhov, M. P., Malakhova, O. A., Kim, K. I., Ritchie, K. J., & Zhang, D.-E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109078200 · Cited by 531
Coccia, E. M., Severa, M., Giacomini, E., Monneron, D., Remoli, M. E., Julkunen, I., Cella, M., Lande, R., & Uzé, G. (2004) · European Journal of Immunology · doi:10.1002/eji.200324610 · Cited by 490
Self-citationZhou, Z., Hamming, O. J., Ank, N., Paludan, S. R., Nielsen, A. L., & Hartmann, R. (2007) · Journal of Virology · doi:10.1128/jvi.02438-06 · Cited by 479
Chen, L., Borozan, I., Feld, J., Sun, J., Tannis, L.-L., Coltescu, C., Heathcote, J., Edwards, A. M., & McGilvray, I. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.059 · Cited by 453
UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity
Malakhova, O. A., Kim, K., Luo, J., Zou, W., Kumar, K. S., Fuchs, S. Y., Shuai, K., & Zhang, D. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601149 · Cited by 431
Honda, M., Sakai, A., Yamashita, T., Nakamoto, Y., Mizukoshi, E., Sakai, Y., Yamashita, T., Nakamura, M., Shirasaki, T., Horimoto, K., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.049 · Cited by 400
Urban, T. J., Thompson, A. J., Bradrick, S. S., Fellay, J., Schuppan, D., Cronin, K. D., Hong, L., McKenzie, A., Patel, K., Shianna, K. V., et al. (2010) · Hepatology · doi:10.1002/hep.23912 · Cited by 361
The Receptor of the Type I Interferon Family
Uzé, G., Schreiber, G., Piehler, J., & Pellegrini, S. (2007) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-71329-6_5 · Cited by 260
Self-citationIL-28 and IL-29: Newcomers to the interferon family
Uzé, G., & Monneron, D. (2007) · Biochimie · doi:10.1016/j.biochi.2007.01.008 · Cited by 260
Self-citationDill, M. T., Duong, F. H. T., Vogt, J. E., Bibert, S., Bochud, P., Terracciano, L., Papassotiropoulos, A., Roth, V., & Heim, M. H. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.039 · Cited by 250
Jaitin, D. A., Roisman, L. C., Jaks, E., Gavutis, M., Piehler, J., Van der Heyden, J., Uze, G., & Schreiber, G. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.5.1888-1897.2006 · Cited by 225
Self-citationDifferential Receptor Subunit Affinities of Type I Interferons Govern Differential Signal Activation
Jaks, E., Gavutis, M., Uzé, G., Martal, J., & Piehler, J. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.11.053 · Cited by 223
Self-citationOsiak, A., Utermöhlen, O., Niendorf, S., Horak, I., & Knobeloch, K.-P. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.15.6338-6345.2005 · Cited by 213
Asselah, T., Bieche, I., Narguet, S., Sabbagh, A., Laurendeau, I., Ripault, M.-P., Boyer, N., Martinot-Peignoux, M., Valla, D., Vidaud, M., et al. (2008) · Gut · doi:10.1136/gut.2007.128611 · Cited by 208
Randall, G., Chen, L., Panis, M., Fischer, A. K., Lindenbach, B. D., Sun, J., Heathcote, J., Rice, C. M., Edwards, A. M., & McGilvray, I. D. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.043 · Cited by 179
Sarasin-Filipowicz, M., Wang, X., Yan, M., Duong, F. H. T., Poli, V., Hilton, D. J., Zhang, D.-E., & Heim, M. H. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00224-09 · Cited by 173
Liu, L., Ilaria, R. L., Kingsley, P. D., Iwama, A., Etten, R. A. V., Palis, J., & Zhang, D. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.3029 · Cited by 164
Pichard‐Garcia, L., Raulet, E., Fabre, G., Ferrini, J.-B., Ourlin, J.-C., & Maurel, P. (2006) · Humana Press eBooks · doi:10.1385/1-59259-998-2:283 · Cited by 138
Self-citationKalie, E., Jaitin, D. A., Podoplelova, Y., Piehler, J., & Schreiber, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806019200 · Cited by 129
Self-citationUbe1L and Protein ISGylation Are Not Essential for Alpha/Beta Interferon Signaling
Kim, K. I., Yan, M., Malakhova, O. A., Luo, J.-K., Shen, M., Zou, W., de la Torre, J. C., & Zhang, D. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.26.2.472-479.2006 · Cited by 127
Coelho, L. F. L., Almeida, G. M. D. F., Mennechet, F. J. D., Blangy, A., & Uzé, G. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502188102 · Cited by 121
Self-citationPotu, H., Sgorbissa, A., & Brancolini, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1942 · Cited by 113
Receptor Density Is Key to the Alpha2/Beta Interferon Differential Activities
Moraga, I., Harari, D., Schreiber, G., Uzé, G., & Pellegrini, S. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01808-08 · Cited by 112
Self-citationChen, L., Borozan, I., Sun, J., Guindi, M. M., Fischer, S. E., Feld, J. J., Anand, N., Heathcote, J., Edwards, A. M., & McGilvray, I. D. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.10.046 · Cited by 105
Reexamination of the Role of Ubiquitin-Like Modifier ISG15 in the Phenotype of UBP43-Deficient Mice
Knobeloch, K., Utermöhlen, O., Kisser, A., Prinz, M., & Horak, I. D. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.11030-11034.2005 · Cited by 101
Marijanovic, Z., Ragimbeau, J., der Heyden, J. V., Uzé, G., & Pellegrini, S. (2007) · Biochemical Journal · doi:10.1042/bj20070605 · Cited by 85
Self-citationSchwer, H., Liu, L., Zhou, L., Little, M.-T., Pan, Z., Hetherington, C. J., & Zhang, D. (2000) · Genomics · doi:10.1006/geno.2000.6148 · Cited by 74
The Basis for Selective E1-E2 Interactions in the ISG15 Conjugation System
Durfee, L. A., Kelley, M. L., & Huibregtse, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804069200 · Cited by 71
Severa, M., Remoli, M. E., Giacomini, E., Ragimbeau, J., Lande, R., Uzé, G., Pellegrini, S., & Coccia, E. M. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1205742 · Cited by 71
Self-citationDendritic cells and cytokines in immune rejection of cancer
Ferrantini, M., Capone, I., & Belardelli, F. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.10.003 · Cited by 59
Slutzki, M., Jaitin, D. A., Yehezkel, T. B., & Schreiber, G. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.05.069 · Cited by 56
Down-modulation of Type 1 Interferon Responses by Receptor Cross-competition for a Shared Jak Kinase
Dondi, E., Pattyn, E., Lutfalla, G., Ostade, X. V., Uzé, G., Pellegrini, S., & Tavernier, J. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104316200 · Cited by 39
Self-citationNegative regulation of type I interferon signaling: facts and mechanisms.
Coccia, E. M., Uzé, G., & Pellegrini, S. (2006) · PubMed · Cited by 32
Self-citation
Cited by
Interferon-stimulated genes: A complex web of host defenses
Schneider, W. M., Chevillotte, M. D., & Rice, C. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120231 · Cited by 3,067
Shared and Distinct Functions of Type I and Type III Interferons
Lazear, H. M., Schoggins, J. W., & Diamond, M. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.025 · Cited by 1,138
Aicardi–Goutières syndrome and the type I interferonopathies
Crow, Y. J., & Manel, N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3850 · Cited by 925
Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation
Zhang, X., Bogunovic, D., Payelle-Brogard, B., Francois-Newton, V., Speer, S. D., Yuan, C., Volpi, S., Li, Z., Sanal, O., Mansouri, D., et al. (2015) · Nature · doi:10.1038/nature13801 · Cited by 558
Self-citationDecoding type I and III interferon signalling during viral infection
Mesev, E. V., LeDesma, R. A., & Ploss, A. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0421-x · Cited by 538
Metadata
- Authors
- François-Newton, V., Magno de Freitas Almeida, G., Payelle-Brogard, B., Monneron, D., Pichard-Garcia, L., Piehler, J., Pellegrini, S., & Uzé, G.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-07-14
- Volume
- 6
- Issue
- 7
- Pages
- e22200
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2023399402
- Cited by
- 269
- References
- 44
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.